Jaisalmer de Frutos-Lucas1, Natalie Frost2, Kirk I Erickson3, Juan M Serrano4, Fernando Maestu5, Simon M Laws6, Belinda M Brown7. 1. Biological and Health Psychology Department, School of Psychology, Universidad Autónoma de Madrid, 28049, Madrid, Spain; Laboratory of Cognitive and Computational Neuroscience (UCM-UPM), Center for Biomedical Technology, 28223 Madrid, Spain; Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, 6027, Australia. Electronic address: jaisalmer.defrutos@ctb.upm.es. 2. School of Psychological Sciences, University of Western Australia, Crawley, Western Australia, 6009, Australia. 3. Department of Psychology, University of Pittsburgh, Pittsburgh, PA, 15260, USA. 4. Biological and Health Psychology Department, School of Psychology, Universidad Autónoma de Madrid, 28049, Madrid, Spain. 5. Laboratory of Cognitive and Computational Neuroscience (UCM-UPM), Center for Biomedical Technology, 28223 Madrid, Spain; Experimental Psychology Department, School of Psychology, Universidad Complutense de Madrid, 28223, Pozuelo de Alarcón, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28029, Madrid, Spain. 6. Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, 6027, Australia; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, 6102, Australia. 7. Discipline of Exercise Science, College of Science, Health, Engineering and Education, Murdoch University, Murdoch, Western Australia, 6150, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.
Abstract
INTRODUCTION: For decades, researchers have tried to understand the moderating effect of APOE ε4 carriage on the relationship between physical activity (PA), brain health and dementia risk. However, this field has produced inconsistent findings. METHOD: We conducted a systematic review of the literature, searching for observational and interventional studies examining the effect of APOE ε4 carriage on the relationships between PA, dementia risk and different markers of brain health. RESULTS: Observational studies using dementia risk as a primary outcome measure generally found that in shorter follow-up periods (up to 10 years) both APOE ε4 carriers and non-carriers benefit from PA, although longer follow-ups showed mixed results. In neuroimaging studies, mainly carriers or both groups showed benefits. Additionally, the association between PA and amyloid burden was more evident among carriers. Overall, studies with greater samples of active APOE ε4 carriers are more likely to report benefits within this group in terms of lower dementia risk and reduced brain pathology. DISCUSSION: Although we have identified some patterns for the modulating effect of APOE ε4 on PA and dementia or brain pathology, the available data is, overall, inconclusive. Heterogeneity in study design, methodology, and outcomes blur the ability to detect clear associations.
INTRODUCTION: For decades, researchers have tried to understand the moderating effect of APOE ε4 carriage on the relationship between physical activity (PA), brain health and dementia risk. However, this field has produced inconsistent findings. METHOD: We conducted a systematic review of the literature, searching for observational and interventional studies examining the effect of APOE ε4 carriage on the relationships between PA, dementia risk and different markers of brain health. RESULTS: Observational studies using dementia risk as a primary outcome measure generally found that in shorter follow-up periods (up to 10 years) both APOE ε4 carriers and non-carriers benefit from PA, although longer follow-ups showed mixed results. In neuroimaging studies, mainly carriers or both groups showed benefits. Additionally, the association between PA and amyloid burden was more evident among carriers. Overall, studies with greater samples of active APOE ε4 carriers are more likely to report benefits within this group in terms of lower dementia risk and reduced brain pathology. DISCUSSION: Although we have identified some patterns for the modulating effect of APOE ε4 on PA and dementia or brain pathology, the available data is, overall, inconclusive. Heterogeneity in study design, methodology, and outcomes blur the ability to detect clear associations.
Authors: Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg Journal: Mol Neurodegener Date: 2022-09-24 Impact factor: 18.879
Authors: Ryan J Dougherty; Erin M Jonaitis; Julian M Gaitán; Sarah R Lose; Brandon M Mergen; Sterling C Johnson; Ozioma C Okonkwo; Dane B Cook Journal: Alzheimers Dement (Amst) Date: 2021-07-12
Authors: Janina Krell-Roesch; Jeremy A Syrjanen; Jelena Bezold; Sandra Trautwein; Bettina Barisch-Fritz; Klaus Boes; Alexander Woll; Erica Forzani; Walter K Kremers; Mary M Machulda; Michelle M Mielke; David S Knopman; Ronald C Petersen; Maria Vassilaki; Yonas E Geda Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.160